Johnson & Johnson (NYSE:JNJ) Stock Position Lowered by First International Bank & Trust

First International Bank & Trust lessened its position in Johnson & Johnson (NYSE:JNJGet Rating) by 29.0% during the first quarter, Holdings Channel reports. The institutional investor owned 2,791 shares of the company’s stock after selling 1,139 shares during the quarter. First International Bank & Trust’s holdings in Johnson & Johnson were worth $494,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of JNJ. Family CFO Inc acquired a new position in shares of Johnson & Johnson in the 4th quarter worth $26,000. Steward Financial Group LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter worth $34,000. Advocacy Wealth Management Services LLC grew its holdings in shares of Johnson & Johnson by 41.4% in the 1st quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock worth $41,000 after acquiring an additional 67 shares during the last quarter. Iron Horse Wealth Management LLC grew its holdings in shares of Johnson & Johnson by 29.9% in the 4th quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company’s stock worth $45,000 after acquiring an additional 61 shares during the last quarter. Finally, Gibson Wealth Advisors LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter worth $49,000. 68.78% of the stock is currently owned by institutional investors.

In related news, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction on Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the transaction, the executive vice president now owns 71,311 shares in the company, valued at approximately $12,336,803. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Robert J. Decker sold 8,462 shares of the business’s stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the transaction, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The disclosure for this sale can be found here. In the last three months, insiders have sold 78,161 shares of company stock worth $13,895,302. 0.35% of the stock is currently owned by insiders.

A number of equities analysts recently issued reports on JNJ shares. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 17th. Daiwa Capital Markets began coverage on Johnson & Johnson in a research report on Wednesday. They set an “outperform” rating for the company. Citigroup dropped their target price on Johnson & Johnson from $210.00 to $205.00 in a report on Tuesday, May 17th. Raymond James boosted their price objective on shares of Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a research report on Wednesday, April 20th. Finally, Sanford C. Bernstein downgraded shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and increased their target price for the stock from $180.00 to $183.00 in a research report on Wednesday, March 16th. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $190.50.

NYSE JNJ opened at $175.74 on Thursday. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt-to-equity ratio of 0.39. The stock has a market capitalization of $462.44 billion, a PE ratio of 23.68, a price-to-earnings-growth ratio of 3.35 and a beta of 0.66. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The company has a 50 day moving average price of $177.66 and a two-hundred day moving average price of $173.09.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings results on Tuesday, April 19th. The company reported $2.67 earnings per share for the quarter, beating analysts’ consensus estimates of $2.60 by $0.07. The business had revenue of $23.43 billion for the quarter, compared to the consensus estimate of $23.62 billion. Johnson & Johnson had a net margin of 20.90% and a return on equity of 36.59%. Johnson & Johnson’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter last year, the firm earned $2.59 EPS. As a group, equities analysts anticipate that Johnson & Johnson will post 10.23 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 7th. Stockholders of record on Tuesday, May 24th were paid a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a dividend yield of 2.57%. The ex-dividend date of this dividend was Monday, May 23rd. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.06. Johnson & Johnson’s dividend payout ratio is 60.92%.

Johnson & Johnson Company Profile (Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.